Leadership and the abaris team
Guided by the visionary leadership of our Chairman, Mr. Surinder Taneja, Abaris has reached remarkable heights, experiencing exponential growth over the last two decades. The strategic and tactical responsibility is held by key promoters and directors Mr. Sahil Taneja and Mr. Sagar Taneja. Notably, their outstanding contributions and sharp acumen in the fields of finance, marketing, and quality control have propelled Abaris to achieve swift expansion globally.
Emphasizing a commitment to quality and excellence, our company is strengthened by a team of seasoned professionals and industry experts, united in the pursuit of our shared objective—to deliver high-quality pharmaceuticals at accessible prices. The team members’ knowledge, skills, and insights gathered over the years give Abaris an unmatched experience in understanding market dynamics and help us move forward.
Abaris Journey - Key Milestones
1
2005
- Inception of the company
- Acquired LVP facility
2
2006-07
- Inception of the company
- Acquired LVP facility
3
2008-09
- New FFS machinery with 100 ml mould
- Contract Manufacturing for industry
4
2010-11
- Distribution of own brands in IV division
- Developed Paracetamol in 100 ml
- WHO GMP approval for LVP Unit
5
2012-15
- Added new FFS machinery for LVPs
6
2016
- Added 100 ml IV machine
- Received approvals from Uganda, Kenya, Congo & Nepal
7
2017
- Set up of SVP injectable plant as per PICS standards [2 ml to 30 ml in GV & GA]
- Regulatory approval from Nigeria
8
2018
- WHO GMP approval for SVP line
- Installed an additional 100 ml machine
9
2019
- Regulatory approval from Yemen
- Started loan licencing
- Doubled production capacity
10
2022-23
- Regulatory approvals from Russia & Philippines
11
2021-22
- GMP approval in Ethiopia
12
2020
- Introduced Euro head line [LVP] for domestic and international business
13
2024 - 25
- Regulatory Approval Tanzania, Iraq
1
2005
- Inception of the company
- Acquired LVP facility
2
2006-07
- Inception of the company
- Acquired LVP facility
3
2008-09
- New FFS machinery with 100 ml mould
- Contract Manufacturing for industry
4
2010-11
- Distribution of own brands in IV division
- Developed Paracetamol in 100 ml
- WHO GMP approval for LVP Unit
5
2012-15
- Added new FFS machinery for LVPs
6
2016
- Added 100 ml IV machine
- Received approvals from Uganda, Kenya, Congo & Nepal
7
2017
- Set up of SVP injectable plant as per PICS standards [2 ml to 30 ml in GV & GA]
- Regulatory approval from Nigeria
8
2018
- WHO GMP approval for SVP line
- Installed an additional 100 ml machine
9
2019
- Regulatory approval from Yemen
- Started loan licencing
- Doubled production capacity
10
2020
- Introduced Euro head line [LVP] for domestic and international business
11
2021-22
- GMP approval in Ethiopia
12
2022-23
- Regulatory approvals from Russia & Philippines
13
2024-25
- Regulatory Approval Tanzania, Iraq